Abbott to develop new glucose-ketone monitoring system

By LabPulse.com staff writers

June 6, 2022 -- Abbott is developing a wearable device that will allow people with type 1 diabetes to continuously monitor glucose and ketone levels.

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation for the device, which will be the same size as the company's FreeStyle Libre 3 sensor, it said.

Continuous monitoring of glucose and ketone levels is crucial for people with type 1 diabetes who are at higher risk of developing diabetic ketoacidosis, according to Abbott.

The company is conducting clinical studies with the system now and will continue to do so into 2023, it said.

Abbott’s STI test gets FDA nod
Abbott announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for a diagnostic test that detects four common sexually...
Abbott's diagnostic sales climb due to COVID testing
Abbott reported that diagnostic sales rose for the fourth quarter of 2021, a trend driven mostly by the purchase of COVID-19 tests. The company also posted...
FDA issues alerts for Abbott Molecular COVID-19 testing kits
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff and healthcare providers of the potential for false-positive results...
Abbott gets EUA for COVID-19, flu, RSV assay
The U.S. Food and Drug Administration has granted Abbott an emergency use authorization (EUA) for its Alinity m Resp-4-Plex molecular assay to detect...
Abbott wins FDA nod for blood test to diagnose concussion
Abbott has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a rapid blood test to assist with the diagnosis of concussions...

Copyright © 2022 LabPulse.com

Last Updated mp 6/6/2022 2:29:56 PM